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Background: Sleep disorders are commonly associated with acute and chronic 
use of alcohol and with abstinence. To date, there are four approved drugs to treat 
alcohol use disorder (AUD): disulfiram, acamprosate, naltrexone, and nalmefene. 
These AUD therapies reduce the craving and risk of relapse into heavy drinking, but 
little is known about their effect on sleep. As recent evidences indicate a crucial role 
of sleep disorders in AUD, claiming that sleep problems may trigger alcohol abuse 
and relapses, it is fundamental to clarify the impact of those drugs on the sleep 
quality of AUD patients. This systematic review aims to answer the question: how 
does the pharmacotherapy for AUD affect sleep?
Methods: We searched PubMed, Embase, CINAHL Plus, Cochrane, and Scopus 
using sleep- and AUD pharmacotherapy-related keywords. The articles included were 
appraised using the CASP checklists, and the risk of bias was assessed following 
the Cochrane risk-of-bias assessment tool. Finally, we pooled sleep outcomes in a 
meta-analysis to measure the overall effect.
Results and Conclusion: We included 26 studies: only three studies focused on 
sleep as a main outcome, two with polysomnography (objective measurement), and 
one with subjective self-reported sleep, while all the other studies reported sleep 
problems among the adverse effects (subjective report). The only study available 
on disulfiram showed reduced REM sleep. Acamprosate showed no/little effect 
on self-reported sleep but improved sleep continuity and architecture measured 
by polysomnography. The two opioidergic drugs naltrexone and nalmefene had 
mainly detrimental effect on sleep, giving increased insomnia and/or somnolence 
compared with placebo, although not always significant. The meta-analysis 
confirmed significantly increased somnolence and insomnia in the naltrexone 
group, compared with the placebo. Overall, the currently available evidences show 
more sleep problems with the opioidergic drugs (especially naltrexone), while 
acamprosate seems to be well tolerated or even beneficial. Acamprosate might be 
a more suitable choice when patients with AUD report sleep problems. Due to the 
paucity of information available, and with the majority of results being subjective, 
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INTRODUCTION
Alcohol use disorder (AUD) is a chronic relapsing brain 
disease characterized by compulsive alcohol use, loss of 
control over alcohol intake, and a negative emotional state 
in absence of alcohol. When people, physically dependent 
on alcohol, stop drinking, they experience a very unpleasant 
alcohol withdrawal syndrome. The symptoms usually resolve 
spontaneously within a week, but more severe forms may 
be associated with generalized seizures, hallucinations, and 
delirium tremens, which can be fatal (Jesse et al., 2017).
To date, the drugs to treat AUD are disulfiram, acamprosate, 
naltrexone, and nalmefene (Figure 1). Disulfiram, well known as 
antabuse, was the first medication approved by the U.S. Food and 
Drug Administration (FDA) to treat alcohol dependence in 1951 
(Kragh, 2008). Disulfiram should only be used in patients who 
are highly motivated to maintain abstinence (Alozai and Sharma 
2019). Its mechanism of action for maintaining alcohol abstinence 
is thought to be primarily psychological (Skinner et al., 2010) 
and based on a highly unpleasant pharmacological consequence 
if alcohol is consumed. In fact, disulfiram blocks the enzyme 
aldehyde dehydrogenase; thus, in the presence of alcohol, elevated 
concentrations of its metabolite acetaldehyde (Figure 1) will result 
in the unpleasant disulfiram-ethanol reaction consisting primarily of 
tachycardia, flushing, nausea, and vomiting (Swift, 1999; Zindel and 
Kranzler, 2014). Therapeutic and adverse effects are therefore closely 
connected: with disulfiram, alcohol becomes a health threat if the 
patient fails to maintain complete abstinence (Mutschler et al., 2016).
Acamprosate, approved by the FDA in 2004 (Kragh, 2008), 
is a drug known to be a glutamate receptor antagonist. In 
line with this, acamprosate is reported to reduce blood (Nam 
et al., 2015) and brain (Frye et al., 2016) glutamate levels. 
It has been suggested that inhibition of glutamate binding 
(Figure 1) occurs via allosteric interaction rather than direct 
competition (Harris et al., 2002). Acamprosate supports 
abstinence by normalizing the often-protracted dysregulation 
of NMDA-mediated glutamatergic neurotransmission that 
follows chronic heavy alcohol use and withdrawal (Mason and 
Crean, 2007). However, acamprosate might be able to reduce 
drinking-related parameters only in a certain percentage of 
alcohol-dependent patients (for review, see Boothby and 
Doering, 2005). Interestingly, recent evidences show that 
serum levels of glutamate are decreased by acamprosate only 
in positive responders, who also show higher baseline levels of 
glutamate with respect to non-responders, suggesting that the 
baseline levels of glutamate could be used as biomarkers of the 
response to acamprosate (Nam et al., 2015).
Use of opioid antagonists appears to reduce certain aspects 
of alcohol drinking in animals (Hyytia and Sinclair, 1993) and 
in humans (Reid et al., 1986). Naltrexone (oral and long-acting 
injectable formulations) is a non-selective opioid receptor 
antagonist (Figure 1) approved by the FDA to treat opioid 
dependence in 1984 (Kragh, 2008). The rationale for the use 
of opioid receptor antagonists to treat alcohol dependence 
dates back to 1980s, when preclinical studies first showed an 
interaction between alcohol and opioid receptors, involving an 
important role for the endogenous opioid system as a mediator of 
the reinforcing effects of alcohol (Hiller et al., 1981). Preclinical 
studies also showed the opioidergic regulation of alcohol and 
alcohol metabolites on drinking behavior (Lucchi et al., 1982; 
Myers et al., 1986; Reid et al., 1986; Peana et al., 2011), supporting 
the potential utility of opioid antagonists to treat alcohol 
dependence. Naltrexone decreases the probability of a return 
to any drinking and binge-drinking risk (Kranzler and Soyka, 
2018). A recent meta-analysis of clinical trials on the effects of 
the naltrexone on alcohol drinking found overall significant 
efficacy, but in several studies, the effects are only minor and/or 
variable (Maisel et al., 2013).
Nalmefene (daily and/or as needed) is an opioid system 
modulator (Figure 1) with antagonist activity on the µ and 
δ opioid receptors as well as a partial agonist activity at the κ 
receptor (Nutt, 2014). This drug is the first and still the only 
pharmacological compound registered for reduced drinking in 
patients with alcohol dependence by the European Medicines 
Agency (EMA, 2010). van den Brink et al. (2013) observed 
significant diminutions of alcohol intake with nalmefene versus 
placebo, and although this drug induces many side effects, it is 
overall well tolerated (van den Brink et al., 2015).
more research on this topic is needed to further inform the clinical practice, ideally 
with more objective measurements such as polysomnography.
Keywords: alcohol use disorders (AUD), sleep disorder, insomnia, pharmacotherapy, disulfiram, acamprosate, 
naltrexone, nalmefene
FIGURE 1 | Mechanism of action of AUD drugs. ADH, alcohol 
dehydrogenase; ALDH, aldehyde dehydrogenase; MEOS, microsomal 
ethanol oxidizing system.
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Generally, these drugs for AUD (disulfiram, acamprosate, 
naltrexone, and nalmefene) have been largely inadequate at 
preventing relapse at a population level, and this may be because 
they only target certain aspects of AUD (Sanchez-Alavez 
et al., 2019). In fact, the complexity of AUD, especially from a 
neurobiological evaluation, makes pharmacologic treatments 
particularly difficult, considering the high co-morbidity 
with mood-related disorders (psychotic, bipolar, depressive, 
anxiety, sexual dysfunction, obsessive-compulsive, delirium, 
neurocognitive) and, in particular, with sleep disorders.
Sleep problems are commonly associated with AUD 
(Figure 2); nonetheless, these symptoms are frequently ignored 
(Brooks and Wallen, 2014). The association between alcohol 
use and sleep disorders seems to be bidirectional (Chakravorty 
et al., 2016), as shown in Figure 2. Acute excess of alcohol intake 
induces sleep; therefore, alcohol is often used by individuals as a 
sleep-promoting agent to self-medicate insomnia (sleep disorder 
in which the quantity or quality of sleep is less than desired; 
Table  2). However, after chronic intake, the hypnotic effect of 
alcohol decreases (Vitiello, 1997). Clinical and preclinical studies 
have shown that chronic alcohol intake usually interferes with 
both sleep architecture (which is the basic structural organization 
of sleep as it shifts into stages that include REM and NREM; 
Table  2) as well as continuity (amount and distribution of sleep 
versus wakefulness) (Crum et al., 2004; Thakkar et al., 2015). On 
the other hand, insomnia is associated with daytime consequences 
that include mood and cognitive alterations (for example, 
reduced ability to concentrate) that might have an impact on the 
quality of life (Buysse, 2008). Worsening of sleep quality in AUD 
patients may increase the drive to use alcohol to self-medicate 
sleep problems, which, in turn, would further impair sleep in 
a dangerous vicious circle (Figure 2). It is therefore suggested 
that sleep problems increase the risk for developing AUD (Teplin 
et al., 2006). Insomnia occurs in 36–72% of alcoholic patients 
and may last for weeks to months during acute abstinence from 
alcohol (Brower, 2003). On the contrary, long-term abstinence 
from alcohol use can reverse some sleep problems (Brower 
et al., 2001), but long-term abstinence is difficult to achieve, and 
insomnia during the initial phase of abstinence might increase 
the risk of relapse (Gottheil et al., 1979; Brower, 2003; Arnedt 
et al., 2007; Chakravorty et al., 2016) as shown in Figure 2. Finally, 
insomnia can persist even after several years of abstinence, with 
more fragmented sleep (i.e., sleep that is interrupted by repetitive 
awakenings) and delayed sleep onset (Brower, 2001; Escobar-
Cordoba et al., 2009).
A growing body of literature highlights the importance of 
addressing sleep problems to support the treatment of AUD, 
especially during acute withdrawal. Nevertheless, sleep problems 
in AUD still remain often untreated, mainly for concerns about 
the safety of additional hypnotic drugs that can potentially 
induce dependence and can interfere with alcohol (Hajak et al., 
2003; Ashton, 2005; Foulds et al., 2018). In this framework, 
it appears particularly important to review the effects of the 
pharmacotherapy for AUD on sleep in order to elucidate how the 
drugs used to treat AUD can improve (or worsen) sleep problems 
during abstinence. The choice of the pharmacotherapy for AUD 
should be informed by evidence on the effects of those drugs on 
sleep. Choosing a drug that has no detrimental effect or could 
even improve sleep during abstinence from alcohol may play an 
important role in the recovery process. Furthermore, improving 
the quality of sleep may as well support other psychosocial 
interventions such as cognitive behavioral therapy for a higher 
therapeutic success. This systematic review with meta-analysis 
aims to determine how the pharmacotherapy for AUD impacts 
the quality of sleep.
METHODS
Overview
The research question was: how does the pharmacotherapy for 
AUD (disulfiram, acamprosate, naltrexone, and nalmefene) affect 
sleep? To answer this question, we followed the preferred reporting 
items statement for reporting on systematic reviews and meta-
analyses (PRISMA; Moher et al., 2009), as shown in Figure 3.
According to the Cochrane handbook recommendations 
(Higgins and Green, 2011), the population (P), intervention 
(I), comparison (C), outcome (O), and study design (S) 
(PICOS model) was used as follows: population, healthy people 
with diagnosis of AUD; intervention, pharmacotherapy for 
AUD (disulfiram, acamprosate, naltrexone, and nalmefene); 
comparison, placebo/other active drug; outcome, sleep (either 
as main outcome or measured as an adverse effect); and study 
design, randomized controlled trial (RCT).
Search Strategy
PubMed, Embase, CINAHL Plus, and Scopus were searched. 
Cochrane was additionally searched to exclude the existence of 
other systematic reviews or protocols on this topic and to use related 
systematic reviews for manual harvesting of additional manuscripts 
through the references. The first database searches were conducted 
in December 2018 and then updated at the end of April 2019.
Boolean “AND,” “OR,” and truncation (*) operators were 
applied to terms related to sleep disorders, alcohol use disorders, 
FIGURE 2 | Relationships between AUD and sleep disorders. Sleep 
disorders may induce alcohol intake for self-medication. In turn, alcohol 
intake, through its neurotoxic effects, may induce sleep disorders. Sleep 
disorders is likewise a risk factor for AUD. Treatment of AUD can lead to 
abstinence, but at the same time, sleep disorders may persist even during 
abstinence. Sleep disorders, in turn, are risk factors for alcohol relapse. At 
the same time, relapse contributes to alcohol neurotoxicity and persistent 
sleep disorders.
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and pharmacotherapy (Table 1). Note that nalmefene was 
not initially included in the keywords, but since the electronic 
database search elicited studies on nalmefene, and given that 
it’s a recently added drug for AUD (Shen, 2018), it was decided 
to include the relative results. Searches were limited to articles 
published in English. The reference sections of relevant reviews 
were also screened for any additional manuscripts not found 
from the electronic database searches.
Eligibility Criteria
Studies were included if they (a) were RCT, as this design 
provides the most reliable evidence about the effects of healthcare 
interventions (Guyatt et al., 2008); (b) sampled individuals with 
AUD; and (c) included any measure of sleep, either as a main 
outcome or among the adverse effects. Studies were excluded if 
they (a) failed to report any sleep outcome; (b) were not RCT 
or pooled data from other RCT studies; (c) sampled individuals 
with specific characteristics other than AUD (e.g., individuals 
genetically screened, and/or with any mental/neurological 
comorbidity); (d) sampled individuals with concomitant 
treatments known to affect sleep (e.g., benzodiazepines, 
antidepressants, other drugs of abuse etc.); (e) focused only 
on drugs other than the drugs indicated for AUD (disulfiram, 
acamprosate, naltrexone, and nalmefene); (f) focused only on 
sleep without AUD; (g) were not original, peer-reviewed articles 
(e.g., reviews, conference papers, letters to editor, guidelines, and 
notes); and (h) were not on humans.
Screening, Data Extraction and Critical 
Appraisal
The two reviewers (FP and ATP) independently extracted the 
data and appraised the quality of the final set of studies, using the 
Critical Appraisal (CASP UK, 2019) checklist for RCT, and any 
disagreements were resolved through consensus. Throughout 
the CASP checklist, reviewers selected “yes” (score: 2) if the 
procedure (e.g., randomization) was cited and clearly described, 
“no” (score: 0) if the procedure was not cited, and “can’t tell” 
(score: 1) if the procedure was only cited but not described. The 
total score from the CASP checklist was also reported in the data 
extraction (Table 3).
For each study, the following information was extracted: 
(1) treatment and design (drug, dose, posology, and duration 
of treatment), (2) population’s characteristics (number of 
subjects per group and sobriety at inclusion), (3) any additional 
psychological support, and (4) outcomes of interest (sleep). 
Results are shown in Table 3.
Risk of Bias
Following the Cochrane risk of bias assessment tool (Higgins and 
Green, 2011), reviewers determined the risk of bias for: selection, 
performance, detection, attrition, reporting, and other biases. 
Using the scores from the CASP checklist (CASP UK, 2019), 
the risk of bias for each domain was rated as: high (CASP: no), 
low (CASP: yes), or unclear (CASP: can’t tell) in the Cochrane’s 
Review Manager (RevMan, 2014) (see Figure 4). It must be 
considered that, since the outcome of interest of this review was 
not the pre-specified outcome of most studies, the relative level of 
risks of selective bias or other biases don’t refer to the outcomes 
FIGURE 3 | Study flow diagram of selected studies (PRISMA).
TABLE 1 | Key words used for the electronic databases search. The “OR” Boolean Operator was used within each column to search for synonyms, while the “AND” 
operator was used between the columns to search for associations of terms. 
OR
AND
OR
AND
OR
AND
OR
Sleep* disorder
Alcohol*
Use Pharmacotherap*
Drug therap*
Sleep* deprivation Abuse
Medication
Drug treatmentSleep* impairment
Consum*
Pharmac* treatment
Sleep* quality
Pharmac* intervention
Ethanol
Addict*
Sleep* disturbance Acamprosate
Dependen* Disulfiram
Insomnia
Antabuse
Withdra*Sleep* problems Naltrexone
Pharmac* therapy
*Truncation operator to search for related words.
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reviewed here. In fact, in all studies where sleep measures were 
reported as adverse effects, it was not possible to determine at 
what point in the study these were assessed and how was the 
sleep quality before the treatment, and this represents a potential 
bias for this review. However, the risk of selective bias and other 
bias was evaluated based on the pre-specified outcomes only, 
following the guidelines.
Outcomes and Meta-Analysis
The outcomes were sleep-related measures, mostly reported as 
adverse effects, and included insomnia, hypersomnia, sleepiness 
(or daytime somnolence, which is a state characterized by 
strong desire for sleep), lethargy, sleep difficulties not otherwise 
specified, and sleep measures from polysomnography (sleep 
onset latency etc), all described in Table 2.
The number of days of sobriety at inclusion was also 
considered, because we a priori know that alcoholism affects 
sleep, even after long periods of abstinence (see Brower, 2001), 
and therefore, we estimated that having a relatively short period 
of sobriety could be an important biasing factor.
For the meta-analysis, we included only studies sharing the same 
drug, dose, comparator, treatment length, and reporting the same 
sleep outcome (insomnia and sleepiness/somnolence), in order to 
minimize the clinical and methodological heterogeneity (Ryan, 2016).
Unfortunately, only five studies with naltrexone met the 
above criteria and were included in the meta-analysis. Of the five 
studies, four reported measures of insomnia, and four reported 
measures of sleepiness (or somnolence; Table 2). All the other 
studies had different design and/or outcomes, and therefore, it 
was not considered appropriate to pool the data together.
All the studies included in the meta-analysis reported 
dichotomous outcomes, which were combined using odds ratio 
(OR). We estimated the pooled OR of insomnia and somnolence 
with its 95% confidence interval (CI) using the inverse variance 
method with random effects meta-analysis model, assuming that 
the true effect size varies between studies (Borenstein et al., 2010). 
Statistical heterogeneity was assessed with the τ2, χ2, and the I2. 
The Z test for overall effect was also performed. The threshold 
of statistical significance was set at p < 0.05. All analyses were 
conducted with the Cochrane’s Review Manager (RevMan, 2014).
RESULTS
Overall Summary of Included Studies
The search produced 5,161 articles (Figure 3). Application of 
the inclusion and exclusion criteria resulted in 26 RCT on the 
efficacy and/or safety of disulfiram, acamprosate, naltrexone, and 
nalmefene. All the relevant characteristics and outcomes of the 
studies are summarized in Table 3.
Five studies were pooled in a meta-analysis (Anton et al., 
1999; Kranzler et al., 2000; Ahmadi and Ahmadi, 2002; Gastpar 
et al., 2002; Baltieri et al., 2008): a total of 645 patients with AUD 
diagnosed with DSM-III-R alcohol dependence (APA. American 
Psychiatric Association, 1987) were included. The mean age 
was 42.2 ± 9.0 for naltrexone and 42.8 ± 9.1 for placebo; most 
patients were males: 76% (naltrexone) vs. 72% (placebo), and two 
studies included only males (Ahmadi and Ahmadi, 2002; Baltieri 
et al., 2008). One study was based in Iran (Ahmadi and Ahmadi, 
TABLE 2 | Sleep terminology.
Daytime sleepiness As somnolence. Excessive daytime 
sleepiness characterized by strong 
desire for sleep.
Somnolence As sleepiness.
Sleep Disorders Symptoms Sleep disturbance. Sleeping difficulty.
Difficulty Falling asleep Initial insomnia.
Difficulty sleeping Difficulty falling asleep or waking up 
several times throughout the night.
Difficulty Staying asleep Trouble remaining asleep.
Hypersomnia A sleep disorder in which someone 
sleeps for very long periods and is 
always very tired during the day.
Inefficient sleep Low sleep efficiency.
Insomnia A sleep disorder in which the quantity 
or quality of sleep is less than desired, 
usually characterized by difficulty 
falling or staying asleep, or waking 
too early, and experiencing daytime 
consequences of reduced sleep.
Lethargy Having little energy; feeling unwilling 
and unable to do anything.
Nightmares/hallucinations A very upsetting or frightening dream/ 
an experience in which you see, hear, 
feel, or smell something that does not 
exist, usually because you are ill or 
have taken a drug.
Polysomnography A technique that records brain activity, 
the oxygen level in the blood, heart 
rate and breathing, as well as eye and 
leg movements in order to study sleep 
and diagnose sleep disorders.
Rapid eye movement (REM) sleep The phase of sleep characterized by 
conjugate eye movements, paralysis 
of other muscles, and brain activity 
that is most similar to wakefulness.
Non-REM (NREM) sleep The collective sleep stages (three in 
total) that are not categorized as REM 
sleep (also called quiescent sleep).
REM sleep latency The amount of time from the onset of 
sleep to the onset of REM sleep.
Sleep efficiency The percent of time in bed spent 
sleeping, calculated as total sleep time 
divided by time in bed.
Sleep latency The amount of time from lights out to 
sleep onset. Sleep onset latency.
Total REM time The amount of REM time during sleep.
Total sleep time The amount of sleep in one complete 
episode of sleep, usually reported in 
minutes.
Total time awake Total period not asleep.
Wake after sleep onset The amount of time awake after 
the onset of sleep and before final 
awakening.
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TABLE 3 | Characteristics of all studies included in the systematic review. Studies are organized by drug, with the name of each drug reported in the first column. 
D
ru
g
Author and 
year
CASP final 
score
Drug dose (N) vs 
comparator (N)
Length of 
treatment
Alcohol
consumption at
inclusion
Additional
(psychological)
support
Sleep-related outcomes
D
is
ul
fi
ra
m
Snyder et al., 
1981
16 Disulfiram 250 mg (13) 
vs Placebo (17)
7 d 3 w of sobriety before 
inclusion
None Number of REM episodes (mean ± SD)
Disulfiram pre 3.69 ± 0.83 post 3.23 ± 0.88c
Placebo pre 3.66 ± 0.77 post 3.56 ± 1.05d
Latency Stage 1-REM (mean ± SD)
Disulfiram pre 68.81 ± 30.65 post 95.27± 
25.44c
Placebo pre 59.78 ± 25.86 post 73.09 ± 
35.07c,d
Total REM Time (mean ± SD)
Disulfiram pre 101.86 ± 25.18 post 83.13 ± 
23.61
Placebo pre 99.65 ± 32.21 post 92.12 ± 
24.56a’b
% Stage 3 (mean ± SD)
Placebo pre 4.49 ± 3.07 post 3.96 ± 3.29d
% Stage 4 (mean ± SD)
Disulfiram pre 5.60 ± 7.80 post 8.74 ± 8.02c
Placebo pre 7.23 ± 8.58 post 5.37 ± 8.48d
a. p < 0.05 pre vs. post
b. p < 0.05 Disulfiram (difference pre-post) vs. 
Placebo (difference pre-post)
c. p < 0.10 pre vs. post
d. p < 0.10 Disulfiram (difference pre-post) vs 
Placebo (difference pre-post)
A
ca
m
p
ro
sa
te Boeijinga 
et al., 2004
11 Acamprosate 2 g/d (12) 
vs Placebo (12)
23 d Alcohol allowed (8 d); 
abstinent 15 d
None During the 8 d run-in period and the 15 d 
withdrawal, insomnia was experienced only 
by placebo subjects (no number of subjects)
Namkoong et 
al., 2003
14 Acamprosate 1.332- 
1.998 g/d (72) vs 
Placebo (70)
8 w No sobriety before 
inclusion
Out-patient 
psychosocial 
intervention
Sleeping difficulty: 8.3% Acamprosate 6/72 
(no data on placebo) and no difference 
with placebo
Perney et al., 
2012
18 Acamprosate 2-3 g/d 
(335) vs Placebo (257)
24 w > 10 d None Sleep Disorders Symptoms (SDS) - Baseline 
Placebo 40.2% vs. Acamprosate 40.7%
SDS-free patients after 6 M
Placebo 34.95% vs. Acamprosate 52.21%  
p  = 0.007
Staner et al., 
2006
14 Acamprosate 0.666 g/d 
(12) vs. Placebo (12)
23 d Alcohol intake allowed 
for the first 8 d then 
abstinent for 15 d
None Day 2 (Withdrawal) - Day 14 (treatment)
Sleep onset latency (min: mean ±SD)
Placebo 25.2 ± 21.3 – 22.7 ± 11.3
Acamprosate 36.6 ± 38.8 – 31.5 ± 20.2
Total sleep time (min: mean ± SD)a*
Placebo 414.9 ± 41.3 – 398.6 ± 59.8
Acamprosate 410.7 ± 35.3 – 402 ± 62
Total time awake (min: mean ± SD)
Placebo 60 ± 45.9 – 84.3 ± 65.6
Acamprosate 64.3 ± 32.9 – 76.9 ± 59.5
Sleep efficiency (%: mean ± SD)a**
Placebo 87.4 ± 9.5 – 82.8 ± 12.9
Acamprosate 86.6 ± 6.9 – 83.9 ± 12.6
Wake after sleep onset (%: mean ± SD)a*,b*
Placebo 8.7 ± 6.6 –13.9 ± 13
Acamprosate 7.9 ± 4.6 –11.5 ±12.1
Stage 1 (%: mean ± SD) Placebo 4.9 ± 2.4 
– 4.5 ± 2.1
Acamprosate 5.4 ± 4.9 – 4.8 ± 2.8
Stage 2 (%: mean ± SD)
Placebo 50.9 ± 5.4 – 49 ± 9.6
Acamprosate 52.7 ± 8.4 – 50.2 ± 10
Stage 3 (%: mean ± SD) b*
Placebo 4.9 ± 2.9 – 4.4 ± 2.2
(Continued)
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TABLE 3 | Continued
D
ru
g
Author and 
year
CASP final 
score
Drug dose (N) vs 
comparator (N)
Length of 
treatment
Alcohol
consumption at
inclusion
Additional
(psychological)
support
Sleep-related outcomes
Acamprosate 5.3 ± 1.9 – 6.2 ± 2.5
Stage 4 (%: mean ± SD)
Placebo 8.9 ± 6.1– 8.8 ± 6.8
Acamprosate 10.5 ± 6.8 – 9.5 ± 6.3
REM sleep (%: mean ± SD)
Placebo 22.4 ± 4.2 – 21.2 ± 5.7
Acamprosate 20.3 ± 5.4 – 18.9 ± 6.4
REM sleep latency (min: mean ± SD) b*
Placebo 66.7 ± 20.3 – 62.6 ± 34.9
Acamprosate 72 ± 18.8 – 82.1 ± 23.5
a) time effect; b) treatment effect *p < 0.05;  
**p < 0.01
A
ca
m
p
ro
sa
te
 +
 N
al
tr
ex
o
ne Anton et al., 
2006
18 No CBI: Naltrexone 
100 mg/d (154) vs. 
Acamprosate 3 g/d 
(152) vs. Naltrexone +
Acamprosate (148) vs. 
Placebo (153)
CBI: Naltrexone (155) 
vs. Acamprosate (151)
vs. Naltrexone + 
Acamprosate (157) vs.
Placebo (156)
CBI only (157)
16 w 4 d CBI only. All 8 
groups with
medications had 
9-session
intervention
focused on 
enhancing
medication 
adherence
and abstinence
Somnolence
Placebo 24%
Acamprosate 31%b
Naltrexone 37%c
Acamprosate + Naltrexone 31%a
a. p < 0.05 vs placebo
b. p < 0.01 vs placebo
c. p < 0.001 vs placebo
Kiefer et al., 
2004
9 Naltrexone 50 mg/d 
(40) vs. Acamprosate
1.998 g/d (40) 
vs Naltrexone + 
Acamprosate
(40) vs. Placebo (40)
12 w 12-15 d Coping skills/
relapse 
prevention group 
therapy
Sleep Disturbance (ns)
Placebo 11.4%
Acamprosate 11.5%
Naltrexone 6.3%
Acamprosate + Naltrexone 11.5%
N
al
tr
ex
o
ne Ahmadi and 
Ahmadi, 
2002
11 Naltrexone 50 mg/d 
(58) vs. Placebo (58)
12 w 3-30 d of
sobriety
before
inclusion
Lethargy
Naltrexone 22.4% vs. Placebo 8.6%
Nightmares/hallucinations
Naltrexone 8.6% vs. Placebo 0%
Insomnia
Naltrexone 17% vs. Placebo 6.9%
Ahmadi et al., 
2004
11 Naltrexone 50 mg/d 
(58) vs. Placebo (58)
36 w 3-30 d of
sobriety
before
inclusion
Training in relapse
prevention (12 
weekly of
30 min sessions 
of
individual 
counselling
sessions
Lethargy (p = 0.04)  
Naltrexone 22.4% vs. Placebo 8.6% 
Nightmares/hallucinations (p = 0.02)  
Naltrexone 8.6% vs. Placebo 0%
Insomnia (p = 0.09)  
Naltrexone 17% vs. Placebo 6.9%
Anton et al., 
1999
16 Naltrexone 50 mg/d 
(68) vs. Placebo (63)
12 w >5 d of
sobriety
before
inclusion
12 weekly 
sessions of
individual 
manual-guided
cognitive 
behavioral
therapy
Daytime sleepiness (p < 0.05) 
Naltrexone 46% vs Placebo 27%
Baltieri et al., 
2008
16 Naltrexone 50 mg/d 
(49) vs. Topiramate 300 
mg/d (52) vs. Placebo 
(54)
12 w 1 w Relapse 
prevention,
counseling and
encouragement 
to
participate in AA 
groups
Placebo vs. Naltrexone vs Topiramate
Insomnia: 5.6% vs 10.2% v.s 9.6% ns
Somnolence: 13.0% vs. 20.4% vs. 13.5% ns
(Continued)
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TABLE 3 | Continued
D
ru
g
Author and 
year
CASP final 
score
Drug dose (N) vs 
comparator (N)
Length of 
treatment
Alcohol
consumption at
inclusion
Additional
(psychological)
support
Sleep-related outcomes
Gastpar 
et al., 2002
16 Naltrexone 50 mg/d 
(84) vs. Placebo (87)
12 Up to 28 d 1 h of 
psychosodal 
treatment every 
wat least
Somnolence (ns) 
Placebo 4% vs. Naltrexone 6%
Insomnia (ns) 
Placebo 5% vs Naltrexone 4%
Heinala et al., 
2001
16 Naltrexone 50 mg/d 
(63) vs. Placebo (58)
12 w + 
20 w as 
needed
1 w Cognitive 
coping skills 
or supportive 
therapy
Insomnia (ns) 
Naltrexone 3.2% vs. Placebo 5.2%
Johnson 
et al., 2004
17 Naltrexone IM 400 mg 
(25) vs. Placebo (5)
4 m > 5 d Psychosocial 
treatment
Somnolence
Naltrexone 12% vs. Placebo 0%
N
al
tr
ex
o
ne
Kranzler 
et al., 2000
14 Naltrexone 50 mg/d 
(61) vs.
Nefazodone 200-400 
mg/d (59)
vs. Placebo (63)
12 w 3-28 d Weekly coping 
skills training
Insomnia (ns)
Placebo 39.7%
Nefazodone 35.6%
Naltrexone 59.0%
Sleepiness (ns)
Placebo 38.1%
Nefazodone 47.5%
Naltrexone 47.5%
Kranzler 
et al., 2003
12 Naltrexone 50 mg/d 
(35) vs.
Naltrexone 50 mg as 
needed
(43) vs. Placebo/d 
(39) vs.
Placebo as needed (36)
8 w Not specified Biweekly 
counseling 
sessions
Difficulty sleeping for 17% of the study 
patients; ns
Krystal et al., 
2001
16 Naltrexone 50 mg/d 
12m (209)
vs. Naltrexone 50 mg/d 
3 m-
Placebo 9m (209) vs. 
Placebo
12 m (209)
12 m > 5 d 12-step facilitation 
counseling (13 m)
Somnolence (ns) 
Naltrexone 5% vs. Placebo 2%
Oslin et al., 
1997
16 Naltrexone 50 mg/d 
(21) vs. Placebo (23)
12 w
(Monday,
Wednesday
and Friday)
>6 w of
sobriety
before
inclusion
Psychosocial 
treatment
Sleep disturbance (average duration in w) ns
Naltrexone 35% (2.9 w)
Placebo 38% (1.4 w)
Oslin et al., 
2008
14 Naltrexone 100 mg/d + 
CBT (40) vs.
Placebo+ CBT (40)
Naltrexone + BRENDA 
(39) vs. Placebo + 
BRENDA (40)
Naltrexone + doctor 
(41) vs. Placebo + 
doctor (40)
24 w 3 d of sobriety
before
inclusion
Psychosocial 
intervention
1. 
Cognitive-
Behavioral 
Therapy (CBT)
2. 
BRENDA
3. 
Doctor: limited 
therapeutic 
content
Insomnia (p < 0.01) Naltrexone 24.2% vs. 
Placebo 11.7%
O’Malley 
et al., 2008
16 Naltrexone 50 mg/d 
(34) vs. Placebo (34)
16 w 4–30 d of  
abstinence
9 sessions 
of medical 
management and 
supportive advice
Sleepiness (p < 0.001)  
Placebo 26% vs. Naltrexone 35%
(Continued)
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2002), two studies in the US (Anton et al., 1999; Kranzler et al., 
2000), one in Brazil (Baltieri et al., 2008), and one in Germany 
(Gastpar et al., 2002; multicentric). The treatment was naltrexone 
50 mg/os/day and lasted for 12 weeks. All studies had placebo 
as comparator; in addition, Baltieri et al. (2008) additionally 
compared with topiramate and Kranzler et al. (2000) compared 
with nefazodone.
Risk of Bias
A total of 26 RCT studies included in the qualitative synthesis were 
appraised with the CASP checklist for RCT (CASP UK, 2019), 
and the final scores (out of 18 points) are reported in Table 3. 
Only one RCT was on disulfiram (Snyder et al., 1981) and was of 
good quality (CASP: 16). Four studies were on acamprosate only, 
and apart from Boeijinga et al. (2004; CASP: 11), they were all 
TABLE 3 | Continued
D
ru
g
Author and 
year
CASP final 
score
Drug dose (N) vs 
comparator (N)
Length of 
treatment
Alcohol
consumption at
inclusion
Additional
(psychological)
support
Sleep-related outcomes
Miranda 
et al., 2014
13 Naltrexone 50 mg (10) 
vs. Placebo (12)
8-10 d No sobriety
before
inclusion
None Difficulty sleeping (ns)  
Naltrexone 19% vs. Placebo 4.8%
N
al
m
ef
en
e Gual et al., 
2013
17 Nalmefene 18 mg (358) 
vs. Placebo (360) as 
needed
24 w Max 14 d BRENDA Insomnia
Nalmefene two times higher than placebo  
(no data available)
Karhuvaara et 
al., 2007
17 Nalmefene 10-40 mg 
(242) vs. Placebo (161) 
as needed
28 w Max 14 d Psychosocial 
intervention 
(minimal)
Insomnia
Nalmefene 31% vs. Placebo 14%
Between group difference (95% Cl)
17 (9.0-25)
Mason et al., 
1999
15 Nalmefene 20 mg/d 
(35); 80 mg/d (35) vs. 
Placebo (35)
12 w 12 w Cognitive 
behavioral 
therapy weekly
Insomnia
Placebo 5.7% vs. Nalmefene 14.3% (ns)
Mason et al., 
1994
16 Nalmefene 10 mg/d (7) 
vs. Nalmefene 40 mg/d 
(7) vs. Placebo (7)
12 w No sobriety
before
inclusion
None Insomnia
Nalmefene 36%
Mann et al., 
2013
18 Nalmefene 18 mg 
(306) vs. Placebo (298) 
as-needed
24 w No sobriety
before
inclusion
BRENDA Sleep disorder
Placebo 0.3% vs. Nalmefene 10.6%
Insomnia  
Placebo 3.4% vs. Nalmefene 9.9%
AA, alcoholics anonymous; BRENDA, biopsychosocial evaluation, report to the patient on assessment, empathic understanding of the patient’s situation, needs collaboratively 
identified by the patient and treatment provider, direct advice to the patient on how to meet those needs, assess reaction of the patient to advice, and adjust as necessary for best 
care; CBI, cognitive behavioral intervention; d, days; w, weeks; m, months; ns, non-significant; IM, intramuscular; SD, standard deviation.
FIGURE 4 | Risk of bias graph: authors’ judgments about each risk of bias presented as percentages across all included studies.
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of relatively good quality (CASP: 14–18; Namkoong et al., 2003; 
Staner et al., 2006; Perney et al., 2012); two RCT studies included 
both acamprosate and naltrexone, one of good quality (CASP: 
18; Anton et al., 2006) and one of lower quality (CASP: 9; Kiefer 
et al., 2004). The majority of RCT (14 studies) were on naltrexone, 
and most of them were of good quality (CASP: 14–17; Oslin et 
al., 1997; Anton et al., 1999; Kranzler et al., 2000; Heinala et al., 
2001; Krystal et al., 2001; Gastpar et al., 2002; Johnson et al., 
2004; Baltieri et al., 2008; Oslin et al., 2008; O’Malley et al., 2008) 
while a few were of moderate quality (CASP: 11–13; Ahmadi and 
Ahmadi, 2002; Kranzler et al., 2003; Ahmadi et al., 2004; Miranda 
et al., 2014). Finally, five RCT studies were on nalmefene, and 
they were all of good quality (CASP: 15–18; Mason et al., 1994; 
Mason et al., 1999; Karhuvaara et al., 2007; Gual et al., 2013; 
Mann et al., 2013).
The risk of selection bias was mainly unclear, as many studies 
failed to describe the randomization procedure, while only few 
studies did (Namkoong et al., 2003; Anton et al., 2006; Karhuvaara 
et al., 2007; Baltieri et al., 2008; O’Malley et al., 2008; Perney et al., 
2012; Mann et al., 2013), and almost none of the studies described 
the allocation concealment, except for Anton et al. (2006), Gual 
et al. (2013), Karhuvaara et al. (2007), and Mann et al. (2013).
The risk of performance and detection bias was also unclear 
for many studies, as only some described the blinding of patients 
and staff (Snyder et al., 1981; Mason et al., 1999; Ahmadi 
and Ahmadi, 2002; Namkoong et al., 2003; Ahmadi  et  al., 
2004;  Johnson et al., 2004; Anton et al., 2006; Baltieri et al., 
2008; O’Malley et al., 2008; Perney et al., 2012; Gual et al., 2013; 
Mann et al., 2013), while the others described the blinding of 
patients only, or did not describe any blinding at all; all studies 
cited a double-blind protocol, except for Kranzler et al. (2000) 
which was clearly single-blind, with high risk of performance 
and detection bias. Finally, most studies had low risk of 
attrition bias, except for Ahmadi et al. (2004), Ahmadi and 
Ahmadi (2002), Boeijinga et al. (2004); Johnson et al. (2004); 
Kranzler et al. (2003); Miranda et al. (2014), and Oslin et al. 
(2008), and low risk of reporting bias, except for Kiefer et  al. 
(2004), Kranzler et  al. (2000); Kranzler et al. (2003); Snyder 
et al. (1981), and Staner et al. (2006), who did not clearly set 
pre-specified primary and secondary outcomes. The detailed 
risks of bias of the studies included in the meta-analysis are also 
reported in (Figure 5, A and B). Of all the trials included in the 
meta-analysis, almost all disclosed the sponsorship, except for: 
Ahmadi and Ahmadi (2002) and Anton et al. (1999).
OUTCOMES
Qualitative Synthesis
Only three studies focused on sleep as a main outcome, 
objectively measured by polysomnography (disulfiram: Snyder 
et al., 1981; acamprosate: Staner et al., 2006) or observed with 
subjective self-reported sleep from a previous set of data (Perney 
et al., 2012). All the other studies reported the sleep problems as 
adverse effects (subjective report).
The main difficulty in the data synthesis was the heterogeneity 
of measurements, as different studies measured different sleep 
outcomes, or the same outcomes described by different terms, or non-
specified generic outcomes (for example, sleep disturbance; Table 2) 
so the data synthesis and meta-analyses were limited. Sleep outcomes 
measured as adverse effects included: insomnia, somnolence, sleep 
disorders symptoms, sleep disorder, sleep disturbance, lethargy, 
nightmares, sleepiness (which here was considered as a synonym 
of somnolence; Table 2), and difficulty sleeping (which here was 
considered synonym of insomnia; Table 2).
In light of the well-known sleep-altering effects of alcohol 
(Brooks and Wallen, 2014), it was necessary to eliminate 
nearly all articles on the effectiveness of disulfiram, since 
this drug is obviously associated with concomitant alcohol 
intake to exert its therapeutic effects. Only one study that 
avoided concomitant use of alcohol, since it focused on 
sleep, was finally included (Snyder et al., 1981). Disulfiram 
overall decreases REM sleep, which is shown by a trend to 
decreased number of REM episodes (p < 0.10), a significantly 
decreased total REM time (p < 0.05), and a trend to increased 
latency to REM stage (p < 0.10), compared with placebo. A 
trend to decreased stage 3 (p < 0.10) was also observed in the 
disulfiram group compared with placebo (Snyder et al., 1981).
Acamprosate had mainly no/little effect on sleep, which 
was reported as adverse effect (except for a significantly higher 
somnolence in the acamprosate group vs. placebo; Anton 
et  al., 2006; p < 0.01). Interestingly, acamprosate seems to give 
less insomnia than placebo, although the difference was not 
significant (Boeijinga et al., 2004). In line with these trends, in the 
only polysomnography study by Staner et al. (2006), acamprosate 
improved both sleep continuity and architecture with respect to 
placebo, as shown by a decreased wake time after sleep onset and 
increased stage 3 and REM sleep latency (p < 0.05 for all measures). 
This is a very important finding as it shows that acamprosate can 
be beneficial to ameliorate sleep parameters typically disturbed 
by AUD. To further confirm the beneficial effects of acamprosate, 
Perney et al. (2012) showed that after 6 months of treatment with 
acamprosate, the number of patients self-reporting sleep disorders 
(symptoms not specified) was decreased with respect to placebo 
(p = 0.07).
Naltrexone generally increased insomnia, although the 
difference with placebo was mostly non-significant, except for one 
study (Oslin et al., 2008; p < 0.01). The strongest effect reported 
was the increased somnolence (or sleepiness) in the naltrexone 
group compared with the placebo, which was significant in three 
studies (Anton et al., 2006; p < 0.001; Anton et al., 1999; p < 0.05; 
O’Malley et al., 2008; p < 0.001) but non-significant in another 
four studies, or the significance was not reported.
Nalmefene gave more insomnia than placebo, although the 
significance was either null or not reported. Somnolence was 
not reported.
Overall, other parameters that were reported for most drugs 
were: lethargy, nightmares/hallucinations, and sleep disorders 
(not specified), but the differences with placebo were non-
significant or the significance was not shown.
Meta-Analysis
Data from five RCT studies (Anton et al., 1999; Kranzler et al., 
2000; Ahmadi and Ahmadi, 2002; Gastpar et al., 2002; Baltieri 
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et  al., 2008) on self-reported insomnia or somnolence were 
grouped together in two meta-analyses performed with the 
Cochrane’s Review Manager (RevMan, 2014).
Insomnia: for a total of 514 individuals, the calculated OR 
was 1.99 (95% CI: 1.16–3.39) (Figure 5A). This indicates a 
significantly higher risk of insomnia with naltrexone compared 
to placebo (p = 0.01). No heterogeneity was detected, with a chi-
square value of 1.87 (p = 0.60) and an I2 of 0%.
Somnolence (daytime sleepiness, Table 2): for a total of 
529 individuals, the calculated OR was 1.85 (95% CI: 1.19–
2.87) (Figure 5B). This indicates a significantly higher risk of 
somnolence with naltrexone compared to placebo (p = 0.006).
No statistically significant heterogeneity was detected with a 
chi-square value of 0.98 (p = 0.81) and an I2 of 0%.
DISCUSSION AND FUTURE DIRECTIONS
To date, this is the first systematic review evaluating the sleep-
related effects of disulfiram, acamprosate, naltrexone, or 
nalmefene reviewed together.
As reported by Snyder et al. (1981), disulfiram decreases REM 
sleep in acute abstinent alcoholics. Interestingly, disulfiram inhibits 
the production of noradrenaline by blocking the dopamine 
β-hydroxylase enzyme (Goldstein et  al., 1964), and this may 
underlie the decreased REM sleep. In fact, although noradrenergic 
neurons show only minimal activity during REM sleep, it is 
recognized that minimal brain stem level of NA is necessary for the 
occurrence of REM sleep (Gottesmann, 2008), as REM sleep can be 
suppressed by lesioning the noradrenergic nucleus, locus coeruleus 
(Jouvet and Delorme, 1965). The disulfiram-induced reduction of 
REM sleep is quite interesting if we consider that during alcohol 
withdrawal, the REM sleep is usually increased (Brower, 2001). In 
addition, other psychiatric disorders often associated with AUD 
and withdrawal, such as depressive disorders, are characterized by 
increased REM sleep, while on the contrary, antidepressant drugs 
reduce REM sleep (see Wichniak et al., 2017). In this framework, 
it could be tempting to suggest that the reduced REM sleep may 
play an important role in the therapeutic effects of disulfiram, 
contributing maybe to mood improvements during abstinence, 
but unfortunately, there are no additional studies on disulfiram to 
further corroborate this hypothesis.
FIGURE 5 | Forest plots of the overall effect of 12-week treatment with naltrexone (50 mg/os/d) or placebo on: insomnia (panel A) and somnolence (panel B). 
Each study is shown by a blue square that represents the odds ratio, with the horizontal lines being the 95% confidence intervals; the pooled Odds Ratio and 95% 
confidence interval by random-effect calculations are depicted as a diamond. Risks of bias are also presented for each study, on the right-up corner.
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Acamprosate shows some beneficial effects on sleep, reducing 
insomnia in some studies (Boeijinga et al., 2004; statistics not 
known), in line with a recent meta-analysis reporting lowered 
insomnia after 6 months of treatment with acamprosate versus 
placebo (Perney and Lehert, 2018). However, in this systematic 
review, we haven’t included most of the studies that were 
analyzed in Perney and Lehert (2018) meta-analysis, mainly for 
lack of sleep outcomes (Pelc et al., 1992; Whitworth et al., 1996; 
Geerlings et al., 1997; Pelc et al., 1997; Poldrugo, 1997; Chick 
et al., 2000; Tempesta et al., 2000; Mason et al., 2006). In fact, 
Perney and Lehert (2018) analyzed the raw sleep data collected 
from those trials. Moreover, two articles on acamprosate were 
excluded because they were not in English (Barrias et  al., 
1997; Ladewig et al., 1993) and another two studies were 
excluded because there was concomitant administration of 
other, potentially biasing, drugs (Besson et al., 1998; Chick 
et al., 2000). Finally, due to the high level of methodological 
heterogeneity across the included studies, we estimated that it 
was not appropriate to pool the data in a meta-analysis. But 
the results summarized in this review suggest beneficial effects 
of acamprosate (Table 3), particularly on parameters of sleep 
continuity and architecture that are usually affected by AUD, 
giving less fragmented sleep, increased deep sleep (stage 3), and 
increased REM sleep latency (Staner et al., 2006). Acamprosate, 
by reducing the glutamatergic neurotransmission (Mason and 
Crean, 2007; Frye et al., 2016), supports abstinence, and this 
might explain the reduced insomnia and the trend to reduce 
REM sleep (Jones, 2019). Glutamate is the major excitatory 
neurotransmitter in the brain and plays an essential role in 
regulating wakefulness and REM sleep (Jones, 2019). Indeed, 
glutamatergic system dysregulation in AUD is a likely substrate 
for several sleep disturbances (Koob and Colrain, 2019).
Naltrexone alters the sleep–wake cycle giving increased 
insomnia and somnolence in some studies, although statistical 
significance was present only in few studies reported in Table 
3 (Anton et al., 1999; Anton et al., 2006; O’Malley et al., 2008; 
Oslin et al., 2008). The higher risk of insomnia and somnolence 
with naltrexone compared to placebo is further confirmed by the 
results showed in the meta-analyses (Figures 5A, B, respectively). 
Despite the lack of evidence on the effect of naltrexone on sleep 
architecture, preliminary results from a recent polysomnography 
study on six healthy males demonstrated that a single dose of 
naltrexone significantly increased stage 2 sleep and decreased 
REM sleep (Sramek et al., 2014). The observed effects on REM 
sleep seem to mimic other drugs such as benzodiazepines, 
tricyclic antidepressants, selective serotonin reuptake inhibitors, 
trazodone, and opioids (Kay et al., 1969; Cronin et al., 1995; 
Obermeyer and Benca, 1996; Gursky and Krahn, 2000; Foldvary-
Schaefer et al., 2002; Barbanoj et al., 2005; Shaw et al., 2005), all 
known to affect the central neurotransmitters involved in the 
sleep–wake cycle, such as catecholamines, acetylcholine, GABA, 
and histamine (Jones, 2019).
Interestingly, it must be noted that there is a common 
signature across these three drugs (disulfiram, acamprosate, 
and naltrexone) in the alteration of sleep architecture. In fact, 
from the few polysomnography studies available, it seems 
that all these drugs decrease the REM sleep (Snyder et al., 
1981; Staner et al., 2006; Sramek et al., 2014), similarly to 
antidepressants (see Wichniak et  al., 2017), although with 
different mechanisms of action.
Finally, similar trends for increased insomnia were observed 
with nalmefene, although much less evidence was available, 
and the statistical significance was null or not reported. These 
results are not surprising, given that both naltrexone and 
nalmefene act on opioid receptors, although with different 
mechanisms. Opioids modulate various neurotransmitters 
including acetylcholine (Illes, 1989; Mulder and Schoffelmeer, 
1993), catecholamines (Gunne, 1959; Moore et al., 1965), and 
GABA (Jalabert et al., 2011; Horsfall and Sprague, 2017), and 
these neurotransmitters are well known to regulate the sleep–
wake cycle (see Jones, 2019). More studies are required to 
establish the exact mechanisms of the opioid-induced effects 
on sleep–wake cycle.
A growing body of literature shows frequent association of 
AUD with sleep disorders (Brower, 2003; Arnedt et al., 2007; 
Angarita et al., 2016). Given that sleep disturbances could have 
a crucial role in the risk of relapse (Brower, 2001), an appropriate 
treatment of sleep problems may support the treatment of 
AUD. The sedative-hypnotic benzodiazepines have been widely 
used to treat sleep problems as well as acute alcohol withdrawal 
(Gensburger and Ghuysen, 2019); however, the use of these drugs 
is not appropriate for people with AUD, for the risk of dangerous 
interactions with alcohol, and for their potential to induce 
dependence (Ashton, 2005). It would be unsafe to prescribe 
benzodiazepines to a population that is clearly more prone to 
developing drug dependence and can relapse into concomitant 
heavy drinking, with the risk of drug-alcohol interaction. Recent 
alternatives to treat sleep disorders in AUD patients involve the 
newer GABA agonist, well known as Z-hypnotics or Z-drugs 
(zolpidem, zopiclone, and zaleplon). These Z-drugs enhance 
GABAA receptor currents via a mechanism that differs from 
that proposed for benzodiazepines (Dixon et al., 2015) and 
are indicated for the treatment of insomnia characterized by 
difficulties with sleep initiation. Although these drugs show lower 
dependence than benzodiazepines, there is still concern over the 
non-negligible potential of abuse of the “Z” hypnotics, which 
would be unsafe in people with history of drug addiction (Hajak 
et al., 2003), and could also interact with alcohol. Recent clinical 
trials have demonstrated that suvorexant, a dual hypocretin/orexin 
receptor, normalizes sleep in patients with primary insomnia. 
More recent studies suggest its potential for the treatment of sleep 
pathology associated with AUD (Sanchez-Alavez et  al.,  2019). 
Campbell et al. (2018) suggested that suvorexant may also 
address key physiological components related with alcohol 
abstinence and withdrawal, such as sleep disorders, which 
should in turn help decrease or inhibit relapse (Campbell et al., 
2018). Although these therapeutic approaches seem promising, 
there is increasing concern around the concomitant use of 
too many drugs in healthcare. Patients with AUD are at high 
risk of pharmacological interactions, due to the incidence of 
comorbidities, the concomitant intake of numerous drugs, and the 
pharmacodynamic and pharmacokinetic interferences of alcohol 
(Guerzoni et al., 2018). On the other hand, the use of hypnotic 
drugs among people with AUD could contribute to overdose 
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mortality, a serious public health concern (Foulds et al., 2018). 
The combination of drugs, called polypharmacy, exposes the 
patients to a dangerous vicious circle, as more drugs means 
more side effects often requiring additional treatments, thus 
increasing the risk of drug interactions (Marengoni and Onder, 
2015). Moreover, a recent systematic review with meta-analysis 
reported that the additional pharmacotherapy of insomnia in 
patients with AUD doesn’t improve alcohol abstinence (Miller 
et al., 2017). Therefore, it is particularly important to elucidate the 
effects of the pharmacotherapy for AUD on sleep quality, as this 
may help tailor the treatment based on the sleep profile of AUD 
patients. A thorough choice of the appropriate pharmacotherapy 
for AUD with the lowest negative impact (or the highest positive 
impact) on sleep may better support the crucial phase of the 
acute withdrawal from alcohol and result in higher success. In 
this respect, it appears that acamprosate is the most beneficial 
(or less detrimental) drug for patients with AUD with history 
of sleep disturbances. However, as highlighted by this review, 
there is no sufficiently detailed data to corroborate this. In 
addition, this systematic review has important limitations, such 
as the inclusion of limited number of articles that are sometimes 
outdated, especially on disulfiram (as this is a relatively old drug). 
Most importantly, as sleep measures were almost always reported 
as adverse effects, it was not possible to determine at what point 
in the study these were assessed and how was the sleep quality 
before the treatment, and this represents a potential bias.
In conclusion, given the high burden that sleep disturbances 
pose on AUD patients, further polysomnography studies to 
elucidate the effects of these drugs on sleep architecture are 
long overdue. More robust evidences on the effect of these 
drugs on sleep architecture may suggest a more holistic 
approach to treat AUD that takes into consideration sleep as 
a crucial element of the therapy, with benefits for the patients 
and maybe higher success.
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